Product Information
APTIVUS 250 MG CAPSULE is a brand product labeled by Boehringer Ingelheim Pharmaceuticals Inc., priced at $16.7859 per EA under NDC 00597000302. Its NADAC has been published 625 times since Nov 28, 2013.
Strength
250 mg/1
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc.NDC
00597000302
Classification
Brand
Dosage Form
CAPSULE, LIQUID FILLED
Route
ORAL
Last Updated
1/1/2025
Active Ingredients
TIPRANAVIRApproval Type
New Drug (NDA)
FDA Application
NDA021814On Market Since
7/1/2005
Pharmacological Classes
Price Statistics
The NADAC for APTIVUS 250 MG CAPSULE has been published 625 times since Nov 28, 2013, and over the history we have for it it has risen 73.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $16.7859 per EA |
|---|---|
| All-time high | $16.7859 (Nov 12, 2025) |
| All-time low | $9.6693 (Nov 28, 2013) |
| 52-week high | $16.7859 |
| 52-week low | $16.7859 |
| Median price | $13.3999 |
| Average price | $13.5483 |
| Largest weekly change | +6.0% (Jan 14, 2015) |
| Weeks tracked | 625 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the tipranavir market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of APTIVUS 250 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for APTIVUS 250 MG CAPSULE, manufactured by Boehringer Ingelheim Pharmaceuticals Inc., is $16.7859 per EA (NDC 00597000302), effective Nov 12, 2025.
How has the price of APTIVUS 250 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for APTIVUS 250 MG CAPSULE has risen 73.6%. It has been tracked across 625 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for APTIVUS 250 MG CAPSULE?
Since Nov 28, 2013, the NADAC for APTIVUS 250 MG CAPSULE has ranged from a low of $9.6693 (Nov 28, 2013) to a high of $16.7859 (Nov 12, 2025), with a median of $13.3999 per EA.
Are there cheaper alternatives to APTIVUS 250 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of APTIVUS 250 MG CAPSULE, so no direct lower-cost alternative is listed.
Who manufactures APTIVUS 250 MG CAPSULE?
APTIVUS 250 MG CAPSULE (NDC 00597000302) is labeled by Boehringer Ingelheim Pharmaceuticals Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification